These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36436121)

  • 21. Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: A 1-year retrospective cohort study.
    Chan HW; Huang CY; Feng WJ; Yen YC
    J Affect Disord; 2016 Nov; 205():360-364. PubMed ID: 27568173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the "real life" management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services.
    Latorre V; Papazacharias A; Lorusso M; Nappi G; Clemente P; Spinelli A; Carrieri G; D'Ambrosio E; Gattullo M; Uva AE; Semisa D
    PLoS One; 2020; 15(3):e0230051. PubMed ID: 32155207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations.
    Schoretsanitis G; Meyer JM; Conca A; Hiemke C
    Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):189-202. PubMed ID: 37259573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study.
    Miura G; Misawa F; Kawade Y; Fujii Y; Mimura M; Kishimoto T
    J Clin Psychopharmacol; 2019; 39(5):441-445. PubMed ID: 31415288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
    Keramatian K; Chakrabarty T; Yatham LN
    CNS Drugs; 2019 May; 33(5):431-456. PubMed ID: 30963507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
    Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
    Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
    [No Abstract]   [Full Text] [Related]  

  • 30. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
    Haddad PM; Taylor M; Niaz OS
    Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
    Fu AZ; Pesa JA; Lakey S; Benson C
    BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study.
    Montemagni C; Del Favero E; Cocuzza E; Vischia F; Rocca P
    Ther Adv Psychopharmacol; 2022; 12():20451253221122526. PubMed ID: 36226272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.
    Pilon D; Joshi K; Tandon N; Lafeuille MH; Kamstra RL; Emond B; Lefebvre P
    Patient Prefer Adherence; 2017; 11():619-629. PubMed ID: 28356723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.
    Wu CS; Hsieh MH; Tang CH; Chang CJ
    J Affect Disord; 2016 Jun; 197():189-95. PubMed ID: 26994437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region.
    Tang CT; Chua EC; Chew QH; He YL; Si TM; Chiu HF; Xiang YT; Kato TA; Kanba S; Shinfuku N; Lee MS; Park SC; Park YC; Chong MY; Lin SK; Yang SY; Tripathi A; Avasthi A; Grover S; Kallivayalil RA; Udomratn P; Chee KY; Tanra AJ; Rabbani MG; Javed A; Kathiarachchi S; Waas D; Myint WA; Sartorius N; Tran VC; Nguyen KV; Tan CH; Baldessarini RJ; Sim K
    Asia Pac Psychiatry; 2020 Dec; 12(4):e12393. PubMed ID: 32468725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
    Llorca PM; Abbar M; Courtet P; Guillaume S; Lancrenon S; Samalin L
    BMC Psychiatry; 2013 Dec; 13():340. PubMed ID: 24359031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.
    Kishimoto T; Hagi K; Nitta M; Leucht S; Olfson M; Kane JM; Correll CU
    Schizophr Bull; 2018 Apr; 44(3):603-619. PubMed ID: 29868849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
    Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
    Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
    Lafeuille MH; Dean J; Carter V; Duh MS; Fastenau J; Dirani R; Lefebvre P
    Curr Med Res Opin; 2014 Aug; 30(8):1643-55. PubMed ID: 24730586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.